Confusing set up>
Word kind of out?
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
CymaBay Therapeutics, Inc.
June 21, 2021, 8:00 AM·7 min read
New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC
NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced positive data from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (PBC).
These data are being presented at The International Liver Congress™ 2021 of the European Association for the Study of Liver (EASL) which will be held online June 23rd – 26th.
In a poster presentation titled “Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies,”1 Stuart C. Gordon MD, Director of Hepatology for Henry Ford Health Systems,
will be reporting the results of a pooled analysis of a subset of 39 patients with compensated cirrhosis from an open-label phase 2 study and a placebo (Pbo) controlled phase 3 study...
A 3 month update which was positive has preceded this- you never say never but it would be very hard to have bad news. Does that stymie the move?